@BlueMatter1

Strategic consulting firm serving the life sciences industry, with operations across the US & Europe; Specialized expertise in oncology, CNS, & rare diseases

bluematterconsulting.com
Joined December 2013
  • Tweets743
  • Following43
  • Followers1.6K
260Media
How to build a Best Practice launch organization (report from our latest study on launch organizational excellence) >> bit.ly/4ed9CmW
1
26
4 key themes from the recent Cell & Gene Meeting on the Mesa in Phoenix, AZ >> bit.ly/4s36GiA
34
We convened 18 sr #biopharma leaders in London to discuss the state of the UK #biotech industry. This group discussed a wide range of topics, including commercialization strategy, finance, people & talent, & program development. Read the synopsis here >> bit.ly/4jOY3WB
1
28
5 issues that biopharma companies must address regarding #psychedelic medicines >> bit.ly/4xWyMxm

From Promise to Practice in Psychedelic Medicines - Blue Matter Consulting

Pharma companies must face these 5 issues as they move psychedelic medicines from clinical promise toward real-world use...

bluematterconsulting.com
39
eBook: 10 success factors for launching & commercializing cell / gene therapies >> bit.ly/4hIi2ox

E-Book: 10 Success Factors for Cell & Gene Therapies - Blue Matter Consulting

When cell / gene therapy launches fail, it's not often the science. It's the launch itself. We lay out 10 critical success factors

bluematterconsulting.com
1
38
5 key issues that #biopharma companies developing #psychedelic therapies will need to address if they are to succeed >> bit.ly/46KWSQf #pharmaceuticals #biotech #CNSTherapies #CNS

The Future of Psychedelic Medicines - Blue Matter Consulting

We explore five critical issues that will shape the path from clinical development to responsible, sustainable real-world use

bluematterconsulting.com
37
Why an early start is critical when building the commercial infrastructure for a cell / gene therapy >> bit.ly/4zQP9O4 #celltherapy #genetherapy #oncology #rarediseases

Success Factors for Commercializing Cell & Gene Therapies (9) - Blue Matter Consulting

For cell / gene therapies, commercial planning and capability development must look quite different. Here, we describe how.

bluematterconsulting.com
34
The latest from our Policy team: The US is the global leader in #biopharma innovation, but will that position last? >> bit.ly/4qE2uoA

Maintaining US Life Science Leadership Requires Policy Focus - Blue Matter Consulting

The US remains the first market for the majority of new medicines, but shifts are happening that could change that...

bluematterconsulting.com
35
NEW >> How internal training & cross-functional coordination can make or break a cell / gene therapy >> bit.ly/4xhOEL5 #celltherapy #genetherapy #oncology #rarediseases

Commercializing Cell & Gene Therapies, part 8 - Blue Matter Consulting

Why cell & gene therapy coordination failures inside the manufacturer often show up as trust failures outside, and how to avoid them.

bluematterconsulting.com
46
Is CMS asking biopharma companies for a number that doesn't exist? The IRA has CMS weigh a drug's R&D costs & whether they've been recouped, but no manufacturer's accounting system produces a per-asset, lifetime figure. Our take on the gap, and a fix: bit.ly/3SjSpjU

The Challenge of R&D Cost Reporting Under the IRA - Blue Matter Consulting

CMS' proposed rules for reporting asset-level R&D costs will place a major burden on pharma. We explore the challenge & a potential solution.

bluematterconsulting.com
39
NEW >> Patient support services for cell / gene therapies & why traditional hub models often fall short >> bit.ly/4wxbnTi #celltherapies #genetherapies #biotech #pharmaceuticals #patientsupport

Patient Support for Cell & Gene Therapies - Blue Matter Consulting

For CGTs, top-level patient support is far more than just a premium add-on...and standard hub models often fall short.

bluematterconsulting.com
28
NEW >> The patient experience & why proper engagement is so important with cell / gene therapies >> bit.ly/4wAqYkD #celltherapy #genetherapy #biotech #pharmaceuticals #patientengagement #patientexperience

The Patient Experience & Cell / Gene Therapies - Blue Matter Consulting

The patient experience is critical to successful commercialization, but it goes well beyond the patient & must embrace the full ecosystem.

bluematterconsulting.com
24
7 Key Themes from #ASCO26 >> bit.ly/3Qno3ME #oncology #cancer #biotech #pharmaceuticals #cencerresearch #ASCO

ASCO 2026 Recap - Blue Matter Consulting

Our team attended ASCO 2026 in Chicago. They noted several key themes that drove conversations there, so here's an overview.

bluematterconsulting.com
44
NEW >> Evidence Generation for #celltherapies & #genetherapies >> bit.ly/3Q87RyO

Cell & Gene Therapies, Evidence Requirements - Blue Matter Consulting

Part 5 in our 10 part series on critical success factors for cell and gene therapies: Supplemental Evidence Generation

bluematterconsulting.com
24
Medical comms that get deployed to the field often become detached from the core strategy that initiated them. For #MedicalAffairs, that's a problem. Here's what to do about it >> bit.ly/4wY3Z3X

When the Message Gets Lost - Blue Matter Consulting

Medical communications can easily become detached from the core strategy behind them. We outline why and what to do about it.

bluematterconsulting.com
46
On May 13, Blue Matter hosted a roundtable discussion with 27 senior biopharma leaders in the Boston area. Now, you can read a summary of these open and insightful conversations: bit.ly/4agCp86 #biotech #pharmaceuticals #biopharma #BlueMatter
31
Our team recently attended the ISPOR 2026 meeting in Philadelphia. Here are 5 key themes they saw at the conference >> bit.ly/3S4pcZM #HEOR #RWE #HealthEconomics #biotech #pharmaceuticals
34
How can you drive access & reimbursement success for a cell / gene therapy? This new article explains why CGT reimbursement is different from specialty pharma, & offers some key success factors for manufacturers. >> bit.ly/3RyMFCj #biotech #pharmaceuticals #celltherapy

Reimbursement Success Factors for Cell & Gene Therapies - Blue Matter Consulting

We outline why reimbursement for CGTs is different from specialty pharma, and what it takes to drive success.

bluematterconsulting.com
1
32
Part 3 in our ongoing series on cell / gene therapies >> bit.ly/4uysKlh

Cell & Gene Therapy Referral Pathways - Blue Matter Consulting

Part 3 in our series on successfully commercializing cell and gene therapies: Understanding Referral Pathways

bluematterconsulting.com
22
NEW REPORT - Key Success Factors for a Best Practice Key Account Management Organization >> bit.ly/42pfB1H #pharmaceutical #biotech #KeyAccountManagement #biopharma #marketaccess
47
Load more